Early Discontinuation of Antibiotics for Community-Acquired Pneumonia

Abstract This chapter appraises a noninferiority trial that tested whether a 3-day course of antibiotics is as effective as an 8-day regimen in hospitalized adults with mild to moderate-severe community-acquired pneumonia (CAP). Researchers conducted a double-blinded, placebo-controlled study across nine Dutch hospitals, randomizing 121 patients who showed substantial clinical improvement after 3 days of intravenous amoxicillin. Both groups achieved similar outcomes in clinical cure, bacteriological and radiological success, symptom resolution, and adverse events at 10 and 28 days. Although the chapter includes limitations—such as small sample size, limited generalizability, and baseline imbalances—it still confirms that shorter antibiotic therapy does not compromise effectiveness. Finally, the chapter emphasizes that early antibiotic discontinuation aligns with stewardship goals by reducing unnecessary exposure, limiting adverse effects, and helping prevent antimicrobial resistance.